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1. Introduction  
The management of dermatological hypersensitivity diseases is a lifelong struggle for most 
patients. Often, patients are advised to avoid triggers and aggregating factors that lead to 
flare ups which eventually becomes second nature to them. However, when the symptoms 
of these conditions become unbearable and conventional medicine no longer provides relief, 
an increasing proportion of allergy patients are looking to alternative treatments for comfort. 
Natural products are compounds isolated from natural sources (usually plants or animals) that 
have potentially beneficial bioactivity. However, many types of compounds can be defined as 
natural bioactives including synthesized molecules that are based upon naturally occurring 
compounds. As such, we will define the term “natural bioactive” as any compound whose 
parent compound structure occurs in nature. Medical research is exploring these compounds 
as potential treatment sources for a myriad of conditions, including the dermatological 
hypersensitivity diseases. With the growing interest in natural health products it could be 
possible that disease sufferers, by self exploring alternative treatments, are potentially leading 
the search towards the next new approved and medically accepted treatment.  
2. Current treatments and management in dermatological hypersensitivity 
diseases  
The management of atopic and hypersensitivity diseases are initially addressed by life style 
modifications. With all hypersensitivity diseases, be it food allergies, contact 
hypersensitivity, or allergic asthma, suffers quickly become aware of their disease triggers 
and begin a lifelong course of avoidance (Custovic et al., 1998). Unknown triggers can be 
identified medically using a skin prick/patch test. This involves a controlled dermal 
exposure to the known and the most frequent allergens, and triggers are identified from the 
resultant skin reactions (Li, 2002). Pharmacological treatments are added into the treatment 
schedule as the severity of disease progresses, following well-developed treatment ladders 
(algorithms) (Schmitt et al., 2008). As the patient moves into the stronger classes of 
treatments in these schedules, the associated side effects become more severe, influencing 
treatment decisions, ultimately compliance rate and exploration of alternative treatments. 
2.1 Life style modifications and diet 
The effect of diet on allergies and atopic diseases mitigation has been well studied, but has 
produced conflicting results (Allan & Devereux, 2011; Devereaux & Yusuf, 2003; Finch et al., 
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2010; Wichers, 2009). In children with a family history of atopic diseases, research has been 
focused towards the effects of maternal diet during pregnancy, lactation, and then 
subsequently in the infant when and which foods are introduced. Of particular interest is 
the effect of probiotics on the development of allergies which will be discussed below 
(section 4.2.4). In patients with food allergies triggers are eliminated from the diet, however 
other foods have been suggested which might be beneficial to allergy suffers. Some of these 
compounds include poly-unsaturated fatty acids (PUFA); Vitamins C (Chang et al., 2009), D, 
E, Zinc, Selenium. However, these findings have been meet with mixed results (Finch et al., 
2010).  
2.2 Medical treatment 
Medical treatments are initiated as the severity of symptoms become worse and the disease 
becomes intolerable (Schmitt et al., 2008). For each condition, drug classes have been 
recommended to be added in a specific order/time in the treatment schedule. However, due 
to the nature of these conditions treatment is individually tailored depending on patient 
response and their tolerance of the side effects. These patients follow a defined treatment 
plan consisting of pharmacological classes, based on their indications and complications. 
When treatment is initiated for a patient, the success of treatment always needs to balance 
with the side effect the treatment has on patient quality of life. (R. Finkel et al., 2009). The 
following is a brief overview of some conventional treatments for hypersensitivity disease 
such as sterioids and anti-histamines. Some of these compounds originated from natural 
sources but have been modified extensively to improve both their efficacy and potency. As 
such, these medications are not strictly considered “naturally sourced.” In section 3 below, 
we will address “naturally sourced” treatments for comparison. 
2.2.1 Corticosteroids 
Corticosterioids are a class of steroid hormones that are frequently used as a first line 
treatment in many immunological and dermatological diseases (Richard Finkel, 2009). They 
can be classified as short to long acting (1-55+ hours) and are applied topically or 
systematically. They are very effective at mitigating inflammation; however, their side 
effects limit their long term use. Many of the new treatments are being sought as 
corticosteroids sparing alternatives (Del Rosso & Friedlander, 2005).  
Mechanism of Action: Corticosteroids bind intracellular receptors forming dimers that bind to 
the glucocorticoid response element of the promoter region of steroid responsive genes, 
which up regulates 10-100 genes (Bolognia et al., 2008). They also act by inhibiting nuclear 
factor kB (NF-κB) which dramatically decreases the inflammatory response through the 
down regulation of certain cytokines, cell adhesion molecules and other inflammatory 
mediators. (Ex: TNFα, GM-CSF, several interleukins (ex. Il-1, IL-2, IL-6, Il-8); Intercellular 
adhesion molecule-1 and E-selectin; cyclooxygenase, etc). (D'Acquisto et al., 2002; Richard 
Finkel, 2009) 
Topical Benefits: Reduced itching, improvements in sleep, appearance of skin, self-esteem and 
quality of life (Miller & Eichenfield, 2006):. Side effects(Miller & Eichenfield, 2006) Short Term 
– stinging on application (for potent preparations); Medium to Long Term – local 
complications (i.e. skin thinning, striate, glaucoma from periocular use, contact sensitization 
and tolerance), etc. ; Systemic effects – suppression of the hypothalamic-pituitary-adrenal 
axis, Cushing’s syndrome, decreased immunity.  
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Systemic Benefits (Miller & Eichenfield, 2006): Relief from itching, skin redness and 
infiltration and reduced oozing; Side Effects(Miller & Eichenfield, 2006): Short term – 
increased appetite, psychosis and dyspepsia; Long term - hypertension, osteoporosis, 
adrenal suppression, striate and muscle atrophy, Cushing’s Syndrome, decreased immunity. 
2.2.2 Emollients 
Emollients are creams designed to alleviate the symptoms of pruritus in dermatitis 
(Bolognia et al., 2008). They are normally applied daily and act by coating the skin and 
creating an artificial barrier. They are composed of either water free or water-in-oil 
ointments with urea (10-20%) or lactic acid (5-12%). The underlying principle of this 
treatment is to ‘correct’ the barrier defect of the skin in AD. Benefits: Reduce skin dryness, 
itching and penetration of skin by irritants and allergens; prevention of skin cracking; 
possible reduced need for topical corticosteroids, possible enhanced response when used 
with topical corticosteroids. Side Effects: Possible stinging on application (R. Finkel et al., 
2009). 
2.2.3 Topical calcineurin inhibitors 
These compounds are among the newest class of immunomodulatory compounds that have 
been approved for use in inflammatory skin diseases (2000) (Grassberger et al., 2004). 
Members of this class include Pimecrolimus, Tacrolimus and Ascomycin. All originated as 
natural products isolated from the fermentation products of the bacteria Streptomyces sp. 
(Richard Finkel, 2009). This class has the advantage of treating AD refractory to 
corticosteroids and reducing the amount of corticosteroids required in severe cases (Spergel 
& Leung, 2006). 
Mechanism of Action: Inhibits calcineurin phosphatase by binding to FK506 binding protein 
which then complexes to calcineurin preventing its activation (Assmann et al., 2000). 
Activated calcineurin dephosphorylates the cytoplasmic subunit of the nuclear factor of 
activated T cells (NFAT), which then translocates to the nucleus where it forms a complex 
that assists in transcription of numerous cytokines (ex. Th1: IL2, INFϒ; Th2: IL4, IL5) 
(Grassberger et al., 1999; Sakuma et al., 2001). 
Indications: (Bolognia et al., 2008) 
Pimecrolmus – Mild to moderate atopic dermatitis, other inflammatory dermatoses 
Tacrolimus – Moderate to severe atopic dermatitis, other inflammatory dermatoses 
Benefits: Reduced itching and improvements in sleep, appearance of skin, self-esteem and 
quality of life (Grassberger et al., 2004; Miller & Eichenfield, 2006) 
Adverse Effects 
Short term – mild stinging or burning upon application; normally improves after a week 
Long term – (>5 years) – Tacrolimus: safety unknown, use with caution with excess 
exposure to UV light; Pimecrolimus: safety profile based on 5 years of use appears good. 
2.2.4 Immunomodulators 
This class of drugs/compounds function by attenuating the immune response underlying 
the hypersensitivity reaction. Some of these compounds have been used as 
immunosuppressants in transplant medicine while others are either components of the 
immune system or a new class of treatments known as ‘biological agents’ which are 
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artificially created monoclonal antibody designed to target errant members of the immune 
system (R. Finkel et al., 2009). Interestingly some of the immunosuppressants have their 
origin as natural products including: cyclosporine (isolotaed from fungus Tolypocladium 
inflatum), mycophenolate mofetil (isolated from fungus Penicillium stoloniferum) tacrolimus 
(isolated from Streptomyces tsukubaensis) as well as others (R. Finkel et al., 2009). 
Interferon γ 
Was investigated for use in atopic dermatitis due to its pathological dysregulation, and was 
found to be effective in short term (Hanifin et al., 1993) and long term studies (Stevens et al., 
1998). However, its low response rate and high costs deter its regular use and 
implementation. 
Biological Agents – Monoclonal Antibodies 
These agents are biologically engineered antibodies directed against specific targets in the 
immune system. Some of these agents have made it to market for specific conditions (see 
table1). Omalizumab is a humanized mouse monocolonal antibody targeting the IgE Fc 
Region. It binds free IgE but not IgE bound to FcεRI on masts cells, so in this way it 
sequesters free IgE without activating bound IgE and causing mast cell degranulation 
(Presta et al., 1993). Omalizumab has been approved by the FDA for use in severe 
recalcitrant asthma (Strunk & Bloomberg, 2006) and has been investigated for severe cases of 
atopic dermatitis with positive results (Lane et al., 2006).  
 
AGENT  TARGET / MOA CONDITION 
Alefacept, Efalizumab 
T-cell activation,  
T-cell trafficking 
Psoriasis 
Etanercept, Infliximab,  
Adalimumab 
TNFα Psoriasis 
Anakinra IL-1 Rheumatoid arthritis 
Rituximab CD20 (B-cells) B-cell mediated skin diseases 
Table 1. Examples of Biological Agents employed in Dermatological Conditions  
Immunosuppresants: Cyclosporine, methotrexate, Mycophenolate mofetil 
These drugs act by modulating different functions of the immune system and decreasing 
their activity. These drugs while very potent in activity require caution in use, because of 
associated side effects including nephro- , neuro-, and hepatictoxicity (R. Finkel et al., 
2009).  
2.2.5 Other medical treatments 
Anti-Microbial:  
This class of pharmaceuticals are commonly used against infections caused by pathological 
secondary barrier defects in the epidermis. Infections can be caused by intense scratching 
leading to excoriations or due to immune suppression from other treatments. Common 
infections associated with atopic dermatitis include bacterial (S. aurues), viral (Molluscum 
contagiosum, HSV) and fungal (Candida sp., Malassezia sp.) (Bolognia et al., 2008). 
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Retinoids 
Retinoids are related to Vitamin A and act by binding nuclear receptors (RAR, RXR) which 
directly and indirectly up regulate gene expression responsible for immune and 
inflammatory responses and proliferation and differentiation of epithelial cells (Bolognia et 
al., 2008). Retinoids require careful consideration before use due to side effects including 
local effects, systemic, psychological but more importantly teratogenic effects (David et al., 
1988).  
Anti-Histamines 
This class of drugs has multiple therapeutic targets including allergic and inflammatory 
conditions, motion sickness and nausea, gastric acid secretion and others (Richard Finkel, 
2009). They play a role in urticaria prevention (Jauregui et al., 2007) and symptomatic 
treatment in other mast cell conditions (Herman & Vender, 2003; Montoro et al., 2007) 
especially for edema control and pruritus.  
Mast Cell Stabilizers 
Members of this class of drugs include cromolyn and nedocromil, and are used in mast cell 
mediated allergic conditions. They function by inhibiting the IgE mediated release of 
histamine by stabilization of the membrane (Corin, 2000).  
2.2.6 Other treatments 
In addition to medicinal treatments prescribed by practitioners are a series of physical and 
alternative treatments. Very popular with dermatological treatment is the use of UV light 
and tanning beds, especially for psoriasis. Although the mechanism of action is unknown, it 
is thought that UV activates Psoralen which inhibits cellular proliferation. In certain 
conditions practitioners may prescribe Ichthyotherapy in which small fish (doctor fish) are 
employed to remove dead skin from lesions. Coal tar (mixture of hydrocarbons) is used as 
an emollient and remains a popular treatment in many dermatological centers (Bolognia et 
al., 2008).  
3. The use of Complementary and Alternative Medicine (CAM) 
Complementary and Alternative Medicine (CAM): Group of diverse medical and health care 
interventions, practices, products or disciplines that are not generally considered as part of 
conventional medicine (NCCAM, 2011) 
Complementary Medicine: Any of a range of medical therapies that fall beyond the scope of 
scientific medicine but may be used alongside it in the treatment of disease and ill health 
(NCCAM, 2011) 
Alternative Medicine: Medical therapies that are used in lieu of conventional therapy 
(NCCAM, 2011), 
(Note: There are many definitions that have been put forward for CAM, these are the ones 
designated by the National Center for Complementary and Alternative Medicine (USA)). 
Recognition of the rising interest and potential importance of Traditional Medicine (TM) 
and CAM lead the WHO to survey its membership on their respective national attitudes and 
regulatory status of this branch of health care. They found in 2005 that 71% of respondents 
have laws, legislative mandates and National regulatory bodies in place for TM/CAM 
(WHO, 2005). In 1991, the United States created the Office of Alternative Medicine to 
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scientifically scrutinize alternative health practices for the benefit of public and health 
professionals knowledge. By 1998, due to increasing interest of the subject, this department 
was expanded into the National Center for Complementary and Alternative Medicine as a 
member institute of the United States Institutes of Health. It was from this department that a 
systematic classification of Complementary and Alternative Medicines was formed and 
grouped into 5 categories (Molassiotis et al., 2005), see Table 1. It is from the biological based 
therapies and the Alternative Medical systems that sources of natural products are being 
explored for as potential disease treatments and being entered into clinical trials. It should 
be noted that treatments from the other groups have entered clinical trials for certain 
conditions with mixed results including massage (Schachner et al., 1998), acupuncture 
(Salameh et al., 2008), meditation (Chida et al., 2007), prayer and others. 
 
CLASSIFICATION EXAMPLES 
I Alternative Medical Systems Traditional Chinese Medicine, Ayruveda 
II Mind-Body Interventions Meditation, Prayer, Healing or Support Groups 
III Biological Based Therapies Herbs, Dietary Supplements, Vitamins 
IV Manipulation and Body Based Massage, Chiropractive, Osteopathy 
V Energy Therapies Qi Gong, Reiki 
Table 2. Classification of CAM devised by Center for Complementary and Alternative 
Medicine 
3.1 Demographics of CAM use in industrialized nations 
There has been a well-recognized trend in the increasing use of CAM among the general 
public (Harris & Rees, 2000; Su & Li, 2011). In the 2002 US National Health Interview Survey 
(NHIS) of 31,044 adults, 36% of adults reported using CAM in the previous 12 months, and 
if a life time prevalence was included, this figure rose to 50% (Barnes et al., 2004). The results 
from the 2007 survey saw the 12 month prevalence figure rise to 38.6% and among those 
positive respondents, the most common CAM was listed as ‘natural products’ (Barnes et al., 
2008). Earlier smaller scale national surveys conducted by Eisenberg et al. found prevalence 
rates of 33.8% in 1990 and 42.1% in 1997, although these values are higher (possibly due to 
the small samples size) it is generally agreed that CAM use is continually increasing 
(Eisenberg et al., 1998). The NHIS surveys identified some demographic characteristics 
common among users which have been confirmed from other studies. CAM use is more 
prevalent among women, adults with higher education, those who engaged in leisure time 
and physical activity, those who had one or more existing health conditions and have made 
frequent medical visits in the past year (Barnes et al., 2008; Eisenberg et al., 1998; Metcalfe et 
al., 2010; Sirois & Gick, 2002). Other identified factors are higher socioeconomic status, being 
married, those who wished to take a more active role in health care decision making and 
most interestingly those with a chronic health condition (Metcalfe et al., 2010; Wiles & 
Rosenberg, 2001). The popularity of CAM use is also recognized in other industrialized 
countries ; the rates for Canada are estimated at 12-20% (Gavin & Boon, 2005) and 46% in 
Germany and 49% in France where alternative treatments are well engrained in the national 
consciousness (Fisher & Ward, 1994). The trend of increasing CAM can be identified from 
Germany (West) with its 12 months prevalence almost doubling since the 1970’s (See Figure 
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1) (Dixon et al., 2003). It should be kept in perspective when looking at the trends of 
TM/CAM use that (as defined by the WHO) up to 80% of the world’s population uses 
TM/CAM as their sole source of health care in the places where Western health care is 
inaccessible ((World Health Organization., 2009). 
 
 
Fig. 1. Reported Use of CAM in Western Germany from 1970s to 2002 
3.2 Patient and user attitude toward CAM 
There have been many attempts to identify the reasons and motivations as to why 
members of the public are exploring alternative options for their well-being and health 
care. A large European study of 956 Cancer patients in 12 countries, found a prevalence 
rate of CAM use of 38.2% (Range of 14.8% to 73.1%). From those who reported using 
CAM therapy they were investigated first, for their motivation and second, how found 
out about them. The most common motivation for CAM use was to increase their body’s 
ability to fight disease (50.7%), followed by improved physical well-being (40.6%), and 
improvement of emotional well-being (35.2%). Sources of information about CAM were 
identified as friends (56.5%), family (29.1%), media (28.4%) and only 18.6% said their 
physician was the source (Molassiotis et al., 2005). Use of CAM is associated with greater 
number of physical symptoms and with symptoms of greater intensity, longer disease 
duration (Sirois & Gick, 2002). The reasons for people to explore alternative treatment are 
varied, but what should be recognized is that are they exploring them. By having 
members of the public vetting these treatments in terms of personal satisfaction gives 
health care workers a unique opportunity by looking at the usage trends in members of 
the public as potential treatments sources.  
3.3 Health care practitioners attitude towards CAM 
The number of visits to practitioners of alternative therapies is now higher than the number 
of visits to all US primary care physicians (Pagan & Pauly, 2005). Physician and health care 
professionals response to CAM has been varied with differences depending on country, 
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region, age, experience and even sex. In a literature review by Sewitch et al found that 
characteristics of physicians whom are more likely to recommend CAM are younger, 
female, less experienced; while those less likely to recommend CAMs were older, male, 
more experienced physicians (Sewitch & Rajput, 2010). Older physicians are less likely to 
use CAMs themselves or recommend it to their family (Kurtz et al., 2003). It should be 
noted that physicians are the most skeptical and least likely to recommend CAMs to 
patients, of all members of the health care profession. Rural health care providers offered 
CAM more frequently than their urban colleagues (Brems et al., 2006). Between 60-80% of 
surveyed physicians express interest in CAM therapy (Corbin Winslow & Shapiro, 2002; 
Milden & Stokols, 2004) but few as 14% have recommended it their patients. Among 
physicians there is prejudice about the different types if CAMs, established practices such 
as acupuncture, chiropractor tend to be surveyed as the most likely to be beneficial to the 
patient; While reiki, bioelectromagnetics, aromatherapy have been ranked by doctors as 
having the least potential to be beneficial or event harmful to the patient (Levine et al., 
2003). 
3.4 CAM and allergies 
In a German study of 351 subjects with hypersensitivity (hay fever, asthma, atopic eczema, 
food allergies), 93 (26%) were found to be users of CAM. Of the 93 users, 94% previously 
were treated conventionally before starting CAM while 3 users used CAM before starting 
conventional treatment. Of those treated conventionally the majority (85%) were treated 
more than 10 years before trying CAM, they also score the efficacy of conventional medicine 
lower in their experience. Their reported motivations for using CAM were: conviction that 
CAM has less side effects (78%), wish to try everything (72%), unsatisfying results from 
conventional medicine (66%), and belief CAM is more natural (61%) (Schafer et al., 2002) . In 
a review of 7 surveys of dermatological patients who used CAM they found life time 
prevalence of 35-65% (Ernst, 2000); among all the surveys they found severity of illness and 
length of disease had the greatest influence on CAM use. In Europe approximately 30% of 
patients with allergies report using CAM and this rises to approximately 50% of patients 
whom required in-patient treatment (Schafer, 2004). The use CAM is related to the severity 
of the symptoms of their conditions, patients who identify with having poor control are 
more likely to explore alternative treatments.  
4. Search for natural products 
Natural products are compounds that have been isolated from a living organism that have 
been found to be biologically active. A large proportion of the medicines in our current 
pharmacopeia have either originate as natural products or are inspired by a natural product 
using it chemical structure as framework on which to build on (Newman & Cragg, 2007). 
These compounds are being explore for, from all facets of nature including CAMs, our 
foodstocks, and on an increasing scale the marine sources. The remainder of the chapter will 
explore some of the natural products undergoing clinical trials for the treatment of Atopic 
dermatitis. Atopic dermatitis was selected due to its complex pathology, its association with 
the atopic march and the availability of an animal model which will be discussed below. The 
test compounds will be discussed below in the context of atopic dermatitis; however some 
of them are being tested in other related dermatological conditions.  
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4.1 Clinical trials 
Any medicinal compound before entering into an approved treatment system (i.e. National 
Pharmacopeia) requires rigorous study and clinical trials, which have a defined set of trial 
steps, before they can be approved for use by National Regulatory bodies. In the United 
States this task is mandated by the Food and Drug Administration (FDA), in Canada by 
Health Canada and in the European Union by the European Medicines Agency (Rawson, 
2000). All drug approvals required an evidence based approach to qualify their efficacy, 
evaluate the potential toxicity, and to prevent any unforeseen harm to patients. It is 
interesting to note that estimates now have the cost of marketed drugs from the R&D stage 
to consumer use at 500 million to 1 billion dollars and at a time frame of up to 10-15 years 
(DiMasi et al., 2003). Only about 1 out of 1000 drugs from the animal testing stage (or 
preclinical phase) make it into clinical trials and from there only 1 in 5-10 eventually become 
approved. In this manner only 21 new drugs were approved by the FDA in 2010, 25 in 2009 
and 21 in 2008 (Kaitin & DiMasi, 2011). However if natural compounds are identified from 
CAM treatment sources already employed by members of the public they may provide new 
treatment options which can enter rigorous evidence based trials which have already been 
vetted by members of the public.  
Pre-Clinical Studies / Phase 0: Pre-clinical studies are conducted as In vitro (cell culture) and In 
Vivo (animal studies) as initial investigations into suspected potential biological activity. 
Phase 0 studies are human trials using microdoses to determine if its biological effects are 
what is expected (Υσηα Ρανι, 2009) 
Phase I: Small scale study of 20-100 healthy subjects, testing the safety, pharmacodynamics 
and pharmacokinetics of the study compound (Streiner & Normam, 2009), consists usually 
of either single or multiple ascending doses trials. 
Phase II: Following the safety approval of drugs in Phase I, these are a small studies of 50-300 
diseased subjects , designed to assess dosing requirements, efficacy, (Streiner & Normam, 
2009) and safety profiles in people with the condition. 
Phase III: Randomized controlled multicenter trials on large group of diseased patients with 
the target condition, this study are used to determine if the study compound has targeted 
therapeutic effects (R. Finkel et al., 2009). 
Phase IV: These studies occur after the drug has enter the market and is known as Post-
Marketing Surveillance. They determine if any adverse events happen in large group of 
patients which were not previously identified. This phase is important is identifying any 
rare adverse events which occur in large treatment populations. This monitoring is 
responsible from removing from market approved drug which later have been found to be 
potentially harmful, examples are Troglitazone (Cohen, 2006; Gale, 2006) and Vioxx (Karha 
& Topol, 2004). 
4.2 Atopic Dermatitis  
Atopic dermatitis (AD) has been recognized since at least the 1500s (Wallach et al., 2005) 
with its first formal medical description in 1933(Wise & Sulzberger, 1933). This condition is 
currently a popular target of medical research due to its increasing incidence (Peroni et al., 
2008; H. Williams, 1992), distressing rash and intense pruritic symptoms(Hanifin & Rajka, 
1980), leading to general negative effects on the patients quality of life (Kiebert et al., 2002) 
and its being refractory to treatment, along with a host of other reasons . With is long 
recognition in recent medical history, has led to many treatment options being made 
available. If any new product is found to possess immunomodulatory effects they tend to be 
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investigated as possible treatments for AD. The remainder of this chapter will look at 
Natural Products and Natural Preparations undergoing clinical trials for the treatment of 
AD.  
 
PHASE PARAMETERS 
Pre-Clinical In-Vitro (Cell Culture) and In Vivo (Animal Studies), determines biological 
activity, toxicity, etc 
I Small group health subjects; Pharmacokinetic and Pharmacodynamic 
properties, Single Ascending Dose, Multiple Ascending Doses 
II Small group diseased subjects, determine dosing requirements, drug 
efficacy 
III Larger group diseased subjects; Randomized Controlled Multicenter trials 
IV Post Marketing Surveillance Trial 
Table 3. Phases of Clinical Trials 
4.2.1 Animal Models: NC/Nga mice 
One of the advantages of research into treatment for atopic dermatitis has been the 
development of an animal model that has been accepted to be representative of the disease 
(Suto et al., 1999). Using this model, researchers are able to easily test products prior to 
proceeding to human clinical trials. NC/Nga mice are a strain that originated from the 
Japanese fancy mice (Nishiki-Nezumi), established as an inbred strain in 1955 (Matsuda et 
al., 1997). Researchers noticed the development of spontaneous dermatitis like lesions that 
appeared just before or after weaning but the cause and pathogenesis had been unclear. A 
study was conducted to compare these lesions to those of human Atopic Dermatitis (Suto et 
al., 1999). Mice raised in specific pathogen free (SPF) air controlled bioclean rooms did not 
develop lesion, but when moved to air uncontrolled rooms, spontaneously several different 
type of lesions developed after 8 weeks. These mice developed clinical signs similar to AD: 
itching, erythema and hemorrhage, edema, superficial erosion, deep excoriation, scaling and 
dryness of the skin, and retarded growth. Infectious causes were ruled out by co-rearing 
with BALB/c mice which did not develop lesions. The histopathological changes which 
were consistent with Atopic Dermatitis as well as clinical labs values such as IgE 
hyperproduction (Matsuda et al., 1997), overproduction of Th2 specific cytokines (Suto et al., 
1999; Vestergaard et al., 1999).  A literature search conducted in May 2011 resulted in 245 
and 185 articles when the following keywords were used together: NC/Nga Mice, Atopic 
Dermatitis. 
4.2.2 Animal trials 
The following is a list of compounds (albeit not exhaustive) investigated using the NC/Nga 
mice model as potential treatments for Atopic Dermatitis. All were oral feeding studies in 
which the test compound was compared to a control. The efficacies of test compounds were 
determined by the improvement in symptoms of skin erythema, edema, excoriations, 
dryness, and scratching behavior. Other parameters measured depended on the trial and 
included plasma Ig levels, cytokines and chemokine profiles, and evaluation of skin 
biopsies. All of these studies had positive outcomes based on the design parameters and 
were recommended by their research teams for use in human clinical trials.  
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Rumex Japonicus Houtt 
Rumex is an herb used in the traditional medical systems originating from Eastern Asian 
countries (Japan, Korea, China) for the treatment of various skin diseases including AD (H. 
S. Lee et al., 2006). Previous studies have shown that it contains components with anti-
oxidant and antibacterial properties (Elzaawely et al., 2005). Identified Bioactive compounds 
include anthraquinone derivatives: emodin, chrysophanol, physcion.  These compounds 
studied from other natural sources are reported to have antibacterial, antifungal, anti-
inflammatory, immunosuppressive and antiviral properties (H. S. Lee et al., 2006) After 42 
days, mice treated with the test compound were found to have significant decreases in the 
severity of all symptoms when compared to the control, particularly the scratching 
behavior, which is the most distressing symptom of AD. There was a decrease in plasma IgE 
and IL4 (which mediate type I hypersensitivity) and noticeable decrease of inflammatory 
changes in the skin biopsies. The results were more pronounced in the higher concentration 
groups indicating this compound causes a dose response (H. S. Lee et al., 2006). 
PG 102 – Actinidia Arguta 
Actinidia Argurta, commonly known as Hardy Kiwi, is a fruit native to Korea, Northern 
China and Siberia. Compound PG102 and isolated from this fruit by Park et al. in 2005 and 
found to have oral immune modulating effects in mice (Park et al., 2005). A follow up study 
conducted to determine the effect on the NC/Nga mice model (Park et al., 2007), found that 
after 9 weeks, PG102 showed statistically significant beneficial effect on AD symptoms and 
scratching behavior, while noted immunomolecular effects showed a decrease in IgE, IgG, 
IL4 while IL12 was increased. Other reported effects including the prevention of 
eosinophilia, decreased levels of eotaxin and TARC, inhibiting the infiltration of 
inflammatory cells into the dermis, preventing the thickening of the epidermis and dermis 
and reduced expression of Th2 mediated cytokines and chemokines (Park et al., 2007). All of 
these effects are beneficial in attenuating the pathophysiological changes seen in Atopic 
dermatitis. Kim et al. tested the extract for efficacy compared to dexamethasone 
(corticosteriod) and tacrolimus and found PG102 attenuated the physical symptoms of AD 
similar to dexamethasone and more efficiently than tacrolimus. It also had positive effects 
on the molecular inflammatory markers as well (ex. IgE, IL4, INFϒ and others). However, all 
three compounds affected the physical changes in the dermis in a similar manner (Kim et al., 
2009). The initial results indicated this compound shows a promising potential for future use 
as an oral dietary supplement for the long term treatment of AD. 
Saururus Chinensis Baill 
Saururus is a perennial herbaceous plant used in Korean folk medicine for the treatment of 
various conditions such as edema, jaundice, gonorrhea and used has been employed as an 
antipyretic, diuretic, and anti-inflammatory agent (Choi et al., 2008). It has been shown to 
have anti-oxidant activity (Y. S. Lee et al., 2004) and has been used in the management of 
various skin diseases including AD in Eastern countries. It contains flavonoids (quercetin, 
quercitrin, isoquercitrin, rutin) as active components which are reported as possessing 
number of biological effects: antiallergic, anti-inflammatory, antiviral, antiproliferative, 
anticarcinogenic (Scalbert & Williamson, 2000). After 63 days this compound was found to 
significantly improve skin severity scores and improved itching behavior, with the higher 
concentration preforming better. Molecular evaluation found a decrease in IgE but no 
changes in IL4.  
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Lyophyllum Decastes 
Lyophyllum is an edible mushroom cultivated in Japan that is commonly known as ‘Fried 
Chicken Mushroom’. In a previous study, 11 polysaccharide extracts were found to have 
anti-tumour activity (Ukawa et al., 2000) particularly (1-3)B-D-Glucan and (1-6)B-D-Glucan. 
In 2006, it was examined for its potential effect on the AD mice model (Ukawa et al., 2007) 
using a 6 week feeding study. At the end of the study the treatment group had significant 
decreases in skin severity scores, as well as decreases in serum IgE, Histamine, and IL-4.  
Persimmon Leaf Extract 
Persimmon is the edible fruit of the Diospyros kaki Thunberg (Ebenanceae) tree which 
grows in China, Korea and Japan (Matsumoto et al., 2002). Kaempferol, a flavonoid 
contained in the leaf, was found to inhibit antigen and calcium ionophore A23187 induced 
histamine release. Kaempferol-3-glucoside (astraglandin) has been shown to have anti-
pruritic effects(Ishiguro & Oku, 1997). Kotani et al. found the leaf extract inhibited the 
release of histamine from human basophilic cell line KU812 (M Kotani, 1999) promoting 
them to study the effect on NC/Nga model (Kotani et al., 2000). A 14 week oral feeding 
study using both Persimmon Leaf extract and Astraglandin alone found both were effective 
in decreasing the severity of skin scores, inhibiting IgE, IL4, IL13 and Histamine release 
(Kotani et al., 2000). A similar follow up study was conducted confirming these earlier 
results and included measurement of Transepidermal water loss (TEWL) (Major pathology 
in AD due to dermal barrier dysfunction) and was found to be improved by the extract 
(Matsumoto et al., 2002).  
Konjac Glucomannan 
Konjac is a plant found in eastern Asia and is very popular in Japan as cooking supplement. 
Two compounds of interest have been isolated from this product and tested as possible 
treatments: Konjac glucomannan which has been tested in mice and Konjac ceramide which 
entered human trials (see section 4.2.4). Glucomannan, a dietary fiber isolated from the 
tubers of Amorphophallus konjac, is a highly viscous polysaccharide composed of glucose and 
mannose residues (Onishi et al., 2005). During the 1970’s dietary fibers were investigated as 
part of the epidemiology of colon cancer (Burkitt, 1971a, 1971b). During mice feeding 
studies it was observed that serum IgE levels decreased and IgA and IgG increased(Lim et 
al., 1997) indicating dietary fibers indirectly influenced immunoglobulin production. This 
theory was investigated in NC/Nga mouse model during an 8 week controlled feeding trial. 
Skin severity symptoms were significantly improved and scratching events were decreased 
to 1/3 to 1/6 of controls. Serologically it almost totally suppressed IgE levels and decreased 
the total Immunoglobulin, with a noted decreased in IL-4 and INFϒ. Since the compound 
suppressed both Th1 and Th2 related cytokines it’s mechanism of action cannot be 
attributed to Th1/Th2 polarization (Onishi et al., 2004, 2005). Follow up studies found that it 
decreased scratching behvaiour in a dose dependent manner (OnishiKawamotoSuzuki et al., 
2007), and prevented IgE class switching in Balb/c mice following injection of keratinocyte 
extract (Oomizu et al., 2006). It was also found to suppress allergic rhinitis like inflammation 
following nasal challenge with ovalabumin (OnishiKawamotoUeda et al., 2007).  
Gyokuheifusan 
This is a traditional Chinese Medicine formulation that has been used for the treatment of 
allergic and respiratory disease (ex. infections, allergic rhinitis, asthma, and others) (Fang et 
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al., 2005).This preparation contains three herbal medications: Astragalus membranaceus, 
Atractylodes ovata, Saposhinkovia divaricate. In a study on the immunomodulatory effects of 
the formulation on allergic asthma, it was found to reduce the severity of asthma through 
normalization of INFϒ/IL4 ratio (Th1/Th2 balance) (Fang et al., 2005). These results were 
hypothesized to extent to AD, after a 4 week oral feeding treatment placebo control study it 
was found that dermatitis severity scores were improved significantly, as well as IgE and 
the IFNϒ/IL4 balance (Nakatsukasa et al., 2009). 
 
COMPOUND  PARAMETER IMPROVEMENT MOLECULAR IMPROVEMENTS 
Rumex Japonicus 
Houtt 
Skin Severity Scores, Scratching 
Behaviour, Skin inflammatory 
Changes 
Decrease IgE, IL4 
PG102 –  
Actinidia Arguta 
Skin Severity Scores, Scratching 
Behaviour; Prevented eosinophilia, 
inflammatory cells entering dermis
Decrease IgE, IgG, IL4, TARC, 
Eotaxin; Increase IL12; Reduce 
expression of Th2 mediated 
cytokines 
Saururis Chinensis 
Baill  
Skin Severity Scores, Scratching 
Behaviour 
Decrease IgE 
Lyophyllum 
Decastes 
Skin Severity Scores, Scratching 
Behaviour 
Decrease IgE, IL4, Histamine 
Persimmon Leaf 
Extract 
Skin Severity Scores, 
Transepidermal Water Loss 
Decrease IgE, IL4, IL13, Histamine,  
Konjac 
Glucomannan 
Skin Severity Scores, Scratching 
Behaviour 
Decrease IgE, Ig, IL4, INFϒ 
Gyokuheifusan Skin Severity Scores Decrease IgE, IFNϒ/IL4 balance 
Table 4. Summary of Treatments Tested in Animal Models 
4.2.3 Human clinical trials 
When clinical trials are conducted for Atopic Dermatitis subjective symptoms such as 
erythema and pruritus, must be converted to objective and uniform results so that they may 
be compared with other studies. The following are some of the most commonly used 
systems and those employed in the following studies: 
Transepidermal Water Loss (TEWL) (Pinnagoda et al., 1990): This is a measure of integrity 
of stratum corneum’s water barrier function; it provides information about the integrity of 
the skin, which becomes compromised in AD and may be influenced and improved with 
treatment. It is measured using tewameter, with units expressed as g/m2/h; with 
improvement indicated by a lower value. 
Blood flow volume (BFV) :Measured as a parameter of inflammation using Laser Blood Flow 
Monitor; Arbitrary unit with improvement indicated by lower values. 
Skin Color (a* Value): Erythema quantified by skin color reflectance it is measured using 
colorimeter  
Visual Scoring – Visual judgment made by clinical investigator, scored 0-5 
SCORAD (SCORing Atopic Dermatitis) (SCORAD, 1993): Standardized method for reporting 
dermatitis severity first published in 1993 by the European Task Force on Atopic Dermatitis, 
allows dermatitis severity to be reported numerically ranging from 0-103. 
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 SCORAD Calculation = A/5 + 7 (B/2) + C 
 
  PARAMETER TOTAL SCORE 
A SPREAD/BODY SURFACE AREA 100 
  Judge based on rule of 9 for body surface area 
B INTENSITY 18 
  Erythema (1-3)   
  Edema (1-3)   
  Oozing/Crusting (1-3)   
  Excoriation (1-3)   
  Lichenification (1-3)   
C SUBJECTIVE SYMPTOMS 20 
  Pruritus (1-10)   
  Insomnia (1-10)   
Table 5. Parameters for SCORAD Calculation 
4.2.4 Human clinical of trials of natural products 
WBI-1001 (IPBD: 2-isopropyl-5-[(E)-2-phenylethenyl] benzene-1,3-diol) 
This compound is derived from a metabolite of a unique group of bacterial symbiots of 
entomopathogenic nematodes. It was found to inhibit inflammatory cytokine secretion by 
activated T cells including: TNFα, INF ϒ as well as inhibit allergic contact dermatitis in a 
mouse edema model (Bissonnette et al., 2010). A phase 2A, double blind, vehicle controlled 
study resulted in statistically significant improvement in SCORAD, pruritus, and the 
amount of affected body surface area. These improvements were reached after 3-5 weeks of 
treatment. A 12 week Phase IIb trial was conducted (NCT01098734) as of June 9th 2011, the 
results are still pending publication.  
Konjac Ceramide 
Konjac ceramide is the second compound of interest isolated from konjac. Ceramides are a 
normal component of the lipid membrane, and their deficiency has been suggested as one of 
the pathological factors resulting in skin barrier disruption (Imokawa et al., 1991), having 
being previously studied in the treatment of dermatitis (Berardesca et al., 2001). 
Glucosylceramides are isolated, purified and produced as a nutritional supplement (Kimata, 
2006) and oral intake has been found to decrease transepidermal water loss in normal adults 
(Miyanishi et al., 2005). Konjac due to its high concentration of ceramide was studied for its 
effect on AD as an oral supplement. Following a 4 week oral feeding trial in 50 children, the 
SCORAD index was significantly improved when compared to the control group. INFϒ and 
IL-12 were significantly increased while IL-4 and IL-13 were decreased indicating a skewing 
of the cytokine pattern towards a Th1 type. Interestingly in this study, ceramide was found 
to attenuate allergen specific response to HDM (house dust mite) and JCP (Japanese cedar 
pollen) by improving skin symptoms and wheal response but had no effect following 
dermal challenge of Egg white, histamine or buckwheat (Kimata, 2006).  
Borage Oil: Gamma-Linolenic Acid 
In patients with AD, an abnormality in metabolism of polysaturated fatty acids (PUFA) is 
commonly observed (Wright, 1991). PUFA are structural components of cell membrane 
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phospholipids which are important in maintaining membrane fluidity (Wright, 1991), as 
well as being important as precursors for pharmacologically active immunological agents (ie 
Eicosanoids) (R. Finkel et al., 2009). Borage oil contains a high content (24%) of ϒ-linolenic 
acid (GLA) which is a metabolite of linoleic acid, one of the essential fatty acids. It is 
postulated an abnormality in essential fatty acid metabolism affects production of GLA and 
its incorporation into membranes, occurs in AD (Horrobin, 2000; Wright, 1991). Previous 
studies have shown GLA supplementation lead to improvements in multiple diseases 
including seborrheic dermatitis in children (Tollesson & Frithz, 1993). In a small Japanese 
study in a pediatric population, undershirts coated with Borage oil were given to 32 children 
in a double-blind, placebo controlled study (Kanehara et al., 2007) . After 2 weeks it was 
found that there was a statistically significant improvement in symptoms of itch and 
erythema, but no improvement papules, erosions, and trans-epidermal water loss (Kanehara 
et al., 2007). In a literature review of 12 trials (oral and topical) on the efficacy of Borage Oil 
in the treatment of AD by Foster et al. in 2010 found that 5 studies show statistically 
significant improvement, while 5 showed borage oil to be ineffective and 2 studies were 
shown only to have partial response (Foster et al., 2010). The efficacy of borage oil in the 
treatment of AD remains questionable, a previous product EpoGam used for treatment of 
AD was removed from market in 2002 in the UK when it was found to be ineffective. This 
product contained primrose oil which contains lower concentration of GLA then borage oil 
but was based on the same pathophysiologic principle(H. Williams, 2003). Borage oil while 
providing some benefit in some studies requires future study to determine its efficacy and it 
remains to be determine if it will be steroid sparing.  
Emollient Therapy 
Emollient therapy is a mainstay in the management of the symptoms of AD 
(Szczepanowska et al., 2008). While studies into the prevention of AD are less common, 
Simpson et al. proposed that ‘skin barrier protection from birth using bland emollients is a 
safe and feasible strategy for AD prevention’ (Simpson et al., 2010). This was based on the 
results from previous studies that found use of petrolatum early in life may be protective 
against AD development, there was trend towards increased TEWL and skin hydration 
before development of AD, use of emollients in premature infants protects against skin 
inflammation and emollients are effective at preventing flares in established AD (Simpson et 
al., 2010). In 20 high risk infants (based on the ISSAC criteria (Asher et al., 2006)) emollient 
therapy was initiated in the first week of life in order to maintain intact skin barrier. After 2 
years it was found that only 15% of subject developed AD when conservative estimates of 
high risk infants would be positive for AD in the range of 30-50% suggesting this treatment 
could have both a protective and preventative effect (Simpson et al., 2010). 
Probiotics 
Living or inactivated organisms that are claimed to exert beneficial effects on health when 
ingested are referred to as Probiotics (Schrezenmeir & de Vrese, 2001). The use of probiotic 
and prebiotics in the field of allergology is a controversial subject, with the results of 
prenatal and postnatal supplementation for the prevention of atopic dermatitis having 
mixed results (J. Lee et al., 2008). Probiotic intestinal colonization is theorized to affect the 
Th1/Th2 immunological maturation prior to the establishment of atopic dermatitis (Gruber 
et al., 2010). Physiologically the normal gut milieu has an immune system that is balance 
between protective mucosal immunity and systemic tolerance. In food allergies the balance 
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is impaired and oral tolerance of dietary antigens is not achieved. Risk Factors for the 
development of food allergy include immature gut barrier and type II Th2 cell skewed 
cytokine profile are present in early infancy. This may lead to atopic sensitization as antigen 
uptake is aberrant and Th2 cells further produce IL4 a cytokine essential for B cell 
differentiation into IgE producing cells and IL5 which is important for eosinophils . Normal 
bacterial flora at birth is shown to counterbalance the Th2 activity and promote oral 
tolerance. The predilection of bacteria to promote the differentiation of Th1 cell lineage may 
be due to specific CpG motif characteristics of bacterial DNA which has been show to 
induce polycolonal B-cell activation and secretion of Th1 Cytokines IL6, IL12 and interferon 
Y (Passeron et al., 2006).The guts of infants born in poor areas of developing countries where 
allergy prevalence is lower, are colonized earlier by enterobacteria, enterococcim lactobacilli, 
and eubacteria and displays a higher turnover of different E. coli strains in the intestinal 
microflora ((Matricardi et al., 2003). In a meta-analysis of 21 studies (1997-2007) by Lee et al. 
(2007) containing 1898 subjects looking at Probiotics in the prevention of atopic dermatitis 
found a risk reduction of 61% in the development of atopic dermatitis in high risk infants (J. 
Lee et al., 2008). Newer studies have found conflicting results (Boyle et al., 2011) so its use 
remains controversial. Strains of bacteria that have been investigated include Lactobacillus 
rhamnosus GG (Gruber et al., 2007), Bifidobacterium lactis (Kukkonen et al., 2007), Mycobacterium 
vaccae and others (Matricardi et al., 2003). In studies of the use of the Probiotics following the 
establishment of AD has been met with mixed results. In one study it was found that while 
probiotics did improve SCORAD results they were not statistically significant when 
compared to placebo (Viljanen et al., 2005) . Other studies have shown the probiotics 
following established AD in children did improve SCORAD (Passeron et al., 2006) .  
St. John’s Wort Cream 
St. John Wort is a family of plants with worldwide distribution accounting for about 370 
species. It has been use as a herbal treatment for depression (Rapaport et al., 2011), ADHD 
(Chan, 2008) and other psychological condition, however without proven clinical effects. It 
has been traditionally used for the topical treatment of wounds, burns, nerve lesions and has 
used as a remedy for eczematous skin conditions (Schempp et al., 2000). Hypericin is a major 
component of St. John wort and has been found to have bioactive properties exhibiting dose 
dependent photosensitizing activity (Schempp et al., 2000). Hyperforin, a second compound, 
was found to have anti-bacterial activity (Gurevich et al., 1971). After a 7 day topical trial, the 
treatment compound was found to significantly improved SCORAD scores. Colony forming 
units of S. aureus were measured, and found to be decreased by the treatment compound 
when compared to control, however not significantly. No molecular markers of 
inflammation were measure in this study.  
Herbal Preparations – Traditional Chinese Medicine 
Multiple trials have been conducted using formulas of traditional Chinese medicine. These 
formulas have a long history of use and documentation within their medical systems. The 
difficulty in investigating these compounds are due to the manner of preparation and 
individuality of the treatment. In a 2007 study by Hon et al. of a five herb formulation (Flos 
lonicerae, Herba menthae, Cortex moutan, Rhizoma atractylodis, Cortex phellodendri) in a placebo 
controlled 12 week oral feeding trial found that while the treatment group and placebo 
group both improved symptoms there was no statistically significance between the two. 
However in the treatment group, the number of days of corticosteroids use during the 
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month was significantly decreased, improving the quality of life of the subject (Hon et al., 
2007). In a follow up study it was found the formulation suppressed brain-derived 
neurotrophic factor (BDNF), Thymus and activation regulated chemokine (TARC), INF-ϒ, 
and TNFα (Leung et al., 2008). 
 
COMPOUND  PARAMETER IMPROVEMENT MOLECULAR IMPROVEMENTS 
WBI-1001 SCORAD, Pruritus, Body Surface 
Area 
Inhibited TNFα, Increased INF ϒ 
Konjac Ceramide SCORAD, Transepidermal Water 
loss, Allergen specific response 
Increased INFϒ, IL12; Decreased 
IL4, IL13 
Borage Oil SCORAD?, Itch, Erythema Metabolism of PUFA 
Emollient Therapy Prevention of AD  
Probiotics   
St. John’s Wort 
Cream 
SCORAD, Decreased Staph. Aureus
CFUs 
 
TCM   
Table 6. Summary of Treatments Tested in Human Clinical Trials 
4.2.5 Approved compounds 
The calcineurin inhibitors are among the most recent example of natural products that had 
been identified having potential biological activity, then successfully proceeded through the 
clinical trial phase and have been approved for use in the treatment of AD and other 
dermatological hypersensitivity conditions.  The following natural product concoction is the 
most recent treatment approved for use in AD by the FDA. Using an understanding of the 
pathophysiology of AD, compounds were selected that targeted different facets of the 
pathology to work in concert in the treatment of AD.  
Atopiclair MAS063D (Atopiclair)  
Hydrolipidic cream developed for the management of Atopic dermatitis, containing 
moisturizing elements and natural products (Belloni et al., 2005): The agent contains a 
combination of the bioactive compounds from Vitis vinifera, glycyrrhetinic acid and 
Hyaluronic acid. Hyaluronic acid is barrier forming and hydrating agent, traditionally used 
as lubricant in surgery (Manuskiatti & Maibach, 1996). It is a naturally occurring 
glycosaminoglycan in the body found in healthy connective tissue and induces tissue 
hydration (traditionally used as lubricant in other areas of medicine – ocular surgery, 
orthopedic surgery).  Telmesterine and extracts from vitis viniferia have been found to have 
anti protease activities, (inhibiting harmful enzymes that exuded by damaged skin; and 
antioxidant effects protecting against free radicals (Belloni et al., 2005). Procyanidins found 
in vitis viniferia have been examined at the vascular endothelium, where they help to prevent 
oxidative damage, they also form a barrier to protect against elastase, collagenase, 
hyaluronidase, and B-glucuronidase. Glycyrrhetinic acid is a compound found to have anti-
inflammatory activity (Teelucksingh et al., 1990) In 2003, the first vehicle controlled, double 
blind study of Atopiclair was conducted in a study group of 20 subjects with contact 
dermatitis. Subjects applied vehicle to one arm and treatment compound to the other and 
were measured at 24, 48 and 72 hours. Results from this compound were promising, with 
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significant improvements in Transepidermal water loss (by 50%), Blood flow volume, Skin 
color, Visual Scoring. Only itch magnitude results fell below significance but showed 
improvement (Hongbo Zhai, 2003). In a follow up study in 2004, Atopiclair was tested in 
patients with Atopic Dermatitis and found significant improvement in all patients after 22 
days. Statistically significant improvements were measure in total body surface area 
affected, Itch score, SCORAD value, and Quality of sleep. In an informal survery following 
the study 93% of subjects responded positively to the product (Belloni et al., 2005). Following 
this study Atopiclair was approved by the FDA for the use in the treatment of atopic 
dermatitis (Abramovitis & Perlmutter, 2007).  
5. Conclusions 
Natural Products have been identified as potential sources of bioactive compounds used in 
the treatment of immune disorders. Historically some of the major and most important 
pharmaceutical compounds have their origin as natural products (Newman & Cragg, 2007). 
Penicillin, discovered as a metabolite of mold in a petri dish, revolutionized the manner in 
which medicine has been practiced since wide spread implementation following World War 
II (R. Finkel et al., 2009). Many of the classes of treatment compounds currently being used 
in immunology and dermatology have originated from natural products. It might hold true 
that the next revolutionary treatment might likewise have its origin from the natural world, 
potentially being already explored by patients looking into CAMs. 
It is inevitable that nature will continue to provide pharmaceutical active compounds that 
will be used in all practices and disciplines of medicine. It is those conducting the 
exploration for these compounds to keep an open mind to the possibility that an already 
employed alternative medicine might provide the next clue or even a source unknown.  
6. References 
Abramovitis, W, & Perlmutter, A. (2007). Atopiclair: its position within a topical paradigm 
for the treatment of atopic dermatitis. Expert Rev. Dermatol, 2(2), 115-119.  
Allan, K., & Devereux, G. (2011). Diet and asthma: nutrition implications from prevention to 
treatment. J Am Diet Assoc, 111(2), 258-268.  
Asher, M. I., Montefort, S., Bjorksten, B., Lai, C. K., Strachan, D. P., Weiland, S. K., et al. 
(2006). Worldwide time trends in the prevalence of symptoms of asthma, allergic 
rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat 
multicountry cross-sectional surveys. Lancet, 368(9537), 733-743.  
Assmann, T., Homey, B., & Ruzicka, T. (2000). Applications of tacrolimus for the treatment 
of skin disorders. Immunopharmacology, 47(2-3), 203-213.  
Barnes, P.M., Bloom, B., & Nahin, R.L. (2008). Complementary and alternative medicine use 
among adults and children: United States, 2007. Natl Health Stat Report(12), 1-23.  
Barnes, P.M., Powell-Griner, E., McFann, K., & Nahin, R.L. (2004). Complementary and 
alternative medicine use among adults: United States, 2002. Adv Data(343), 1-19.  
Belloni, G., Pinelli, S., & Veraldi, S. (2005). A randomised, double-blind, vehicle-controlled 
study to evaluate the efficacy and safety of MAS063D (Atopiclair) in the treatment 
of mild to moderate atopic dermatitis. Eur J Dermatol, 15(1), 31-36.  
Berardesca, E., Barbareschi, M., Veraldi, S., & Pimpinelli, N. (2001). Evaluation of efficacy of 
a skin lipid mixture in patients with irritant contact dermatitis, allergic contact 
www.intechopen.com
 
Natural Products and Dermatological Hypersensitivity Diseases 453 
dermatitis or atopic dermatitis: a multicenter study. Contact Dermatitis, 45(5), 280-
285.  
Bissonnette, R., Chen, G., Bolduc, C., Maari, C., Lyle, M., Tang, L., et al. (2010). Efficacy and 
safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a 
phase 2A, randomized, placebo-controlled clinical trial. Arch Dermatol, 146(4), 446-
449.  
Bolognia, Jean, Jorizzo, Joseph L., & Rapini, Ronald P. (2008). Dermatology (2nd ed. / edited 
by Jean L. Bolognia, Joseph L. Jorizzo, Ronald P. Rapini ; associate and artwork 
editor, Julie V. Schaffer. ed.). St. Louis, Mo. ; London: Mosby Elsevier. 
Boyle, R. J., Ismail, I. H., Kivivuori, S., Licciardi, P. V., Robins-Browne, R. M., Mah, L. J., et al. 
(2011). Lactobacillus GG treatment during pregnancy for the prevention of eczema: 
a randomized controlled trial. Allergy, 66(4), 509-516.  
Brems, C., Johnson, M. E., Warner, T. D., & Roberts, L. W. (2006). Patient requests and 
provider suggestions for alternative treatments as reported by rural and urban care 
providers. Complement Ther Med, 14(1), 10-19.  
Burkitt, D. P. (1971a). Epidemiology of cancer of the colon and rectum. Cancer, 28(1), 3-13.  
Burkitt, D. P. (1971b). Possible relationships between bowel cancer and dietary habits. Proc R 
Soc Med, 64(9), 964-965.  
Chan, E. (2008). St. John's Wort does not show benefit for ADHD in short trial. J Pediatr, 
153(5), 724.  
Chang, H. H., Chen, C. S., & Lin, J. Y. (2009). High dose vitamin C supplementation 
increases the Th1/Th2 cytokine secretion ratio, but decreases eosinophilic 
infiltration in bronchoalveolar lavage fluid of ovalbumin-sensitized and challenged 
mice. J Agric Food Chem, 57(21), 10471-10476.  
Chida, Y., Steptoe, A., Hirakawa, N., Sudo, N., & Kubo, C. (2007). The effects of 
psychological intervention on atopic dermatitis. A systematic review and meta-
analysis. Int Arch Allergy Immunol, 144(1), 1-9.  
Choi, M. S., Kim, E. C., Lee, H. S., Kim, S. K., Choi, H. M., Park, J. H., et al. (2008). Inhibitory 
effects of Saururus chinensis (LOUR.) BAILL on the development of atopic 
dermatitis-like skin lesions in NC/Nga mice. Biol Pharm Bull, 31(1), 51-56.  
Cohen, J. S. (2006). Risks of troglitazone apparent before approval in USA. Diabetologia, 
49(6), 1454-1455.  
Corbin Winslow, L., & Shapiro, H. (2002). Physicians want education about complementary 
and alternative medicine to enhance communication with their patients. Arch Intern 
Med, 162(10), 1176-1181.  
Corin, R. E. (2000). Nedocromil sodium: a review of the evidence for a dual mechanism of 
action. Clin Exp Allergy, 30(4), 461-468.  
Custovic, A., Simpson, A., Chapman, M. D., & Woodcock, A. (1998). Allergen avoidance in 
the treatment of asthma and atopic disorders. Thorax, 53(1), 63-72.  
D'Acquisto, F., May, M. J., & Ghosh, S. (2002). Inhibition of nuclear factor kappa B (NF-B): 
an emerging theme in anti-inflammatory therapies. Mol Interv, 2(1), 22-35.  
David, M., Hodak, E., & Lowe, N. J. (1988). Adverse effects of retinoids. Med Toxicol Adverse 
Drug Exp, 3(4), 273-288.  
Del Rosso, J., & Friedlander, S. F. (2005). Corticosteroids: options in the era of steroid-
sparing therapy. J Am Acad Dermatol, 53(1 Suppl 1), S50-58.  
www.intechopen.com
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 454 
Devereaux, P. J., & Yusuf, S. (2003). The evolution of the randomized controlled trial and its 
role in evidence-based decision making. J Intern Med, 254(2), 105-113.  
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: new 
estimates of drug development costs. J Health Econ, 22(2), 151-185.  
Dixon, Anna, Riesberg, Annette, Weinbrenner, Susanne, Saka, Omer, Grand, Julian Le, & 
Busse, Reinhard. (2003). Complementary and Alternative Medicine in the UK and 
Germany: Research and Evidence on Supply and Demand (pp. 128). London: Anglo-
German Foundation for the Study of Industrial Society  
Eisenberg, D. M., Davis, R. B., Ettner, S. L., Appel, S., Wilkey, S., Van Rompay, M., et al. 
(1998). Trends in alternative medicine use in the United States, 1990-1997: results of 
a follow-up national survey. JAMA, 280(18), 1569-1575.  
Elzaawely, A. A., Xuan, T. D., & Tawata, S. (2005). Antioxidant and antibacterial activities of 
Rumex japonicus HOUTT. Aerial parts. Biol Pharm Bull, 28(12), 2225-2230.  
Ernst, E. (2000). The usage of complementary therapies by dermatological patients: a 
systematic review. Br J Dermatol, 142(5), 857-861.  
Fang, S. P., Tanaka, T., Tago, F., Okamoto, T., & Kojima, S. (2005). Immunomodulatory 
effects of gyokuheifusan on INF-gamma/IL-4 (Th1/Th2) balance in ovalbumin 
(OVA)-induced asthma model mice. Biol Pharm Bull, 28(5), 829-833.  
Finch, J., Munhutu, M. N., & Whitaker-Worth, D. L. (2010). Atopic dermatitis and nutrition. 
Clin Dermatol, 28(6), 605-614.  
Finkel, R., Clark, M., & Cubeddu, L. (2009). Pharmacology (4th ed.). Philadelphia: Lippincott 
Williams & Wilkins. 
Finkel, Richard. (2009). Pharmacology (4th ed.). Baltimore: Lippincott Williams & Wilkins. 
Fisher, P., & Ward, A. (1994). Complementary medicine in Europe. BMJ, 309(6947), 107-111.  
Foster, R. H., Hardy, G., & Alany, R. G. (2010). Borage oil in the treatment of atopic 
dermatitis. Nutrition, 26(7-8), 708-718.  
Gale, E. A. (2006). Troglitazone: the lesson that nobody learned? Diabetologia, 49(1), 1-6.  
Gavin, J. A., & Boon, H. (2005). CAM in Canada: places, practices, research. Complement Ther 
Clin Pract, 11(1), 21-27.  
Grassberger, M., Baumruker, T., Enz, A., Hiestand, P., Hultsch, T., Kalthoff, F., et al. (1999). 
A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: 
in vitro pharmacology. Br J Dermatol, 141(2), 264-273.  
Grassberger, M., Steinhoff, M., Schneider, D., & Luger, T. A. (2004). Pimecrolimus -- an anti-
inflammatory drug targeting the skin. Exp Dermatol, 13(12), 721-730.  
Gruber, C., van Stuijvenberg, M., Mosca, F., Moro, G., Chirico, G., Braegger, C. P., et al. 
(2010). Reduced occurrence of early atopic dermatitis because of immunoactive 
prebiotics among low-atopy-risk infants. J Allergy Clin Immunol, 126(4), 791-797.  
Gruber, C., Wendt, M., Sulser, C., Lau, S., Kulig, M., Wahn, U., et al. (2007). Randomized, 
placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic 
dermatitis in infancy. Allergy, 62(11), 1270-1276.  
Gurevich, A. I., Dobrynin, V. N., Kolosov, M. N., Popravko, S. A., & Riabova, I. D. (1971). 
[Antibiotic hyperforin from Hypericum perforatum L]. Antibiotiki, 16(6), 510-513.  
Hanifin, J. M., & Rajka, G. (1980). Diagnositic features of atopic dermatitis. Acta Derm 
Venereol (Stockh), Suppl 92, 44-47.  
www.intechopen.com
 
Natural Products and Dermatological Hypersensitivity Diseases 455 
Hanifin, J. M., Schneider, L. C., Leung, D. Y., Ellis, C. N., Jaffe, H. S., Izu, A. E., et al. (1993). 
Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol, 
28(2 Pt 1), 189-197.  
Harris, P., & Rees, R. (2000). The prevalence of complementary and alternative medicine use 
among the general population: a systematic review of the literature. Complement 
Ther Med, 8(2), 88-96.  
Herman, S. M., & Vender, R. B. (2003). Antihistamines in the treatment of dermatitis. J Cutan 
Med Surg, 7(6), 467-473.  
Hon, K. L., Leung, T. F., Ng, P. C., Lam, M. C., Kam, W. Y., Wong, K. Y., et al. (2007). 
Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of 
atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J 
Dermatol, 157(2), 357-363.  
Hongbo Zhai, Clarissa D Villarama, Zeba Hasan Hafeez, Howard I Maiback. (2003). Efficacy 
of a Topical Agent, MAS063D ('Atopiclair'), in the Treatment of Sodium Lauryl 
Sulphate-Induced Irritant Contact Dermatitis. Exog Dermatol, 2, 301-305.  
Horrobin, D. F. (2000). Essential fatty acid metabolism and its modification in atopic eczema. 
Am J Clin Nutr, 71(1 Suppl), 367S-372S.  
Imokawa, G., Abe, A., Jin, K., Higaki, Y., Kawashima, M., & Hidano, A. (1991). Decreased 
level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in 
atopic dry skin? J Invest Dermatol, 96(4), 523-526.  
Ishiguro, K., & Oku, H. (1997). Antipruritic Effect of Flavonol and 1,4-Naphthoquinone 
Derivatives form Impatiens balsamina L. Phytotherapy Research, 11, 343-347.  
Jauregui, I., Ferrer, M., Montoro, J., Davila, I., Bartra, J., del Cuvillo, A., et al. (2007). 
Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol, 
17 Suppl 2, 41-52.  
Kaitin, K. I., & DiMasi, J. A. (2011). Pharmaceutical innovation in the 21st century: new drug 
approvals in the first decade, 2000-2009. Clin Pharmacol Ther, 89(2), 183-188.  
Kanehara, S., Ohtani, T., Uede, K., & Furukawa, F. (2007). Clinical effects of undershirts 
coated with borage oil on children with atopic dermatitis: a double-blind, placebo-
controlled clinical trial. J Dermatol, 34(12), 811-815.  
Karha, J., & Topol, E. J. (2004). The sad story of Vioxx, and what we should learn from it. 
Cleve Clin J Med, 71(12), 933-934, 936, 938-939.  
Kiebert, G., Sorensen, S. V., Revicki, D., Fagan, S. C., Doyle, J. J., Cohen, J., et al. (2002). 
Atopic dermatitis is associated with a decrement in health-related quality of life. Int 
J Dermatol, 41(3), 151-158.  
Kim, J. Y., Lee, I. K., Son, M. W., & Kim, K. H. (2009). Effects of orally administered Actinidia 
arguta (Hardy Kiwi) fruit extract on 2-chloro-1,3,5-trinitrobenzene-induced atopic 
dermatitis-like skin lesions in NC/Nga mice. J Med Food, 12(5), 1004-1015.  
Kimata, H. (2006). Improvement of atopic dermatitis and reduction of skin allergic 
responses by oral intake of konjac ceramide. Pediatr Dermatol, 23(4), 386-389.  
Kotani, M., Matsumoto, M., Fujita, A., Higa, S., Wang, W., Suemura, M., et al. (2000). 
Persimmon leaf extract and astragalin inhibit development of dermatitis and IgE 
elevation in NC/Nga mice. J Allergy Clin Immunol, 106(1 Pt 1), 159-166.  
Kukkonen, K., Savilahti, E., Haahtela, T., Juntunen-Backman, K., Korpela, R., Poussa, T., et 
al. (2007). Probiotics and prebiotic galacto-oligosaccharides in the prevention of 
www.intechopen.com
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 456 
allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin 
Immunol, 119(1), 192-198.  
Kurtz, M. E., Nolan, R. B., & Rittinger, W. J. (2003). Primary care physicians' attitudes and 
practices regarding complementary and alternative medicine. J Am Osteopath Assoc, 
103(12), 597-602.  
Lane, J. E., Cheyney, J. M., Lane, T. N., Kent, D. E., & Cohen, D. J. (2006). Treatment of 
recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol, 54(1), 68-72.  
Lee, H. S., Kim, S. K., Han, J. B., Choi, H. M., Park, J. H., Kim, E. C., et al. (2006). Inhibitory 
effects of Rumex japonicus Houtt. on the development of atopic dermatitis-like skin 
lesions in NC/Nga mice. Br J Dermatol, 155(1), 33-38.  
Lee, J., Seto, D., & Bielory, L. (2008). Meta-analysis of clinical trials of probiotics for 
prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol, 
121(1), 116-121 e111.  
Lee, Y.S., Baek, Y.I., Kim, J.R., Cho, H.K., Sok, D.E., & Jeong, H.S. (2004). Antioxidant 
activities of a new lignan and a neolignan from Saururus chinensisis. Bioorganic & 
Medicinal Chemistry Letters, 14, 5623-5628.  
Leung, T. F., Wong, K. Y., Wong, C. K., Fung, K. P., Lam, C. W., Fok, T. F., et al. (2008). In 
vitro and clinical immunomodulatory effects of a novel Pentaherbs concoction for 
atopic dermatitis. Br J Dermatol, 158(6), 1216-1223.  
Levine, S. M., Weber-Levine, M. L., & Mayberry, R. M. (2003). Complementary and 
alternative medical practices: training, experience, and attitudes of a primary care 
medical school faculty. J Am Board Fam Pract, 16(4), 318-326.  
Li, J. T. (2002). Allergy testing. Am Fam Physician, 66(4), 621-624.  
Lim, B., Yamada, K., Nonaka, M., Kuramoto, Y., Hung, P., & Sugano, M. (1997). Dietary 
fibers modulate indices of intestinal immune function in rats. J Nutr, 127(5), 663-
667.  
M Kotani, A Fujita, T Tanaka. (1999). Inhibitory effects of persimmon leaf extract on allergic 
reaction in human basophilic leukemic cells and mice. J Jpn Soc Nutr Food Sci, 52, 
147-151.  
Manuskiatti, W., & Maibach, H. I. (1996). Hyaluronic acid and skin: wound healing and 
aging. Int J Dermatol, 35(8), 539-544.  
Matricardi, P., Bjorksten, B., Bonini, S., Bousquet, J., Djukanovic, R., Dreborg, S., et al. (2003). 
Microbial products in allergy prevention and therapy. Allergy, 58(6), 461-471.  
Matsuda, H., Watanabe, N., Geba, G. P., Sperl, J., Tsudzuki, M., Hiroi, J., et al. (1997). 
Development of atopic dermatitis-like skin lesion with IgE hyperproduction in 
NC/Nga mice. Int Immunol, 9(3), 461-466.  
Matsumoto, M., Kotani, M., Fujita, A., Higa, S., Kishimoto, T., Suemura, M., et al. (2002). 
Oral administration of persimmon leaf extract ameliorates skin symptoms and 
transepidermal water loss in atopic dermatitis model mice, NC/Nga. Br J Dermatol, 
146(2), 221-227.  
Metcalfe, A., Williams, J., McChesney, J., Patten, S. B., & Jette, N. (2010). Use of 
complementary and alternative medicine by those with a chronic disease and the 
general population--results of a national population based survey. BMC 
Complement Altern Med, 10, 58.  
Milden, S. P., & Stokols, D. (2004). Physicians' attitudes and practices regarding 
complementary and alternative medicine. Behav Med, 30(2), 73-82.  
www.intechopen.com
 
Natural Products and Dermatological Hypersensitivity Diseases 457 
Miller, Alicia D, & Eichenfield, Lawrence F. (2006). Evolving management of atopic 
dermatitis. Expert Review of Dermatology, 1(1), 31-41.  
Miyanishi, K., Shiono, N., Shirai, H., Dombo, M., & Kimata, H. (2005). Reduction of 
transepidermal water loss by oral intake of glucosylceramides in patients with 
atopic eczema. Allergy, 60(11), 1454-1455.  
Molassiotis, A., Fernadez-Ortega, P., Pud, D., Ozden, G., Scott, J. A., Panteli, V., et al. (2005). 
Use of complementary and alternative medicine in cancer patients: a European 
survey. Ann Oncol, 16(4), 655-663.  
Montoro, J., Sastre, J., Jauregui, I., Bartra, J., Davila, I., del Cuvillo, A., et al. (2007). Allergic 
rhinitis: continuous or on demand antihistamine therapy? J Investig Allergol Clin 
Immunol, 17 Suppl 2, 21-27.  
Nakatsukasa, Hiroko, Tago, Fumitoshi, Okamoto, Takuya, Tsukimoto, Mitsutoshi, & 
Kojima, Shuji. (2009). Therapeutic Effects of Gyokuheifusan on NC/Nga Mouse 
Model of Allergic Dermatitis. Journal of Health Science, 55(4), 516-524.  
NCCAM. (2011). Exploring the science of complementary and alternative medicine : third strategic 
plan, 2011-2015. Bethesda, Md.: U.S. Dept. of Health and Human Services, National 
Institutes of Health. 
Newman, D. J., & Cragg, G. M. (2007). Natural products as sources of new drugs over the 
last 25 years. J Nat Prod, 70(3), 461-477.  
Onishi, N., Kawamoto, S., Nishimura, M., Nakano, T., Aki, T., Shigeta, S., et al. (2004). The 
ability of konjac-glucomannan to suppress spontaneously occurring dermatitis in 
NC/Nga mice depends upon the particle size. Biofactors, 21(1-4), 163-166.  
Onishi, N., Kawamoto, S., Nishimura, M., Nakano, T., Aki, T., Shigeta, S., et al. (2005). A 
new immunomodulatory function of low-viscous konjac glucomannan with a small 
particle size: its oral intake suppresses spontaneously occurring dermatitis in 
NC/Nga mice. Int Arch Allergy Immunol, 136(3), 258-265.  
Onishi, N., Kawamoto, S., Suzuki, H., Santo, H., Aki, T., Shigeta, S., et al. (2007). Dietary 
pulverized konjac glucomannan suppresses scratching behavior and skin 
inflammatory immune responses in NC/Nga mice. Int Arch Allergy Immunol, 
144(2), 95-104.  
Onishi, N., Kawamoto, S., Ueda, K., Yamanaka, Y., Katayama, A., Suzuki, H., et al. (2007). 
Dietary pulverized konjac glucomannan prevents the development of allergic 
rhinitis-like symptoms and IgE response in mice. Biosci Biotechnol Biochem, 71(10), 
2551-2556.  
Oomizu, S., Onishi, N., Suzuki, H., Ueda, K., Mochizuki, M., Morimoto, K., et al. (2006). Oral 
administration of pulverized Konjac glucomannan prevents the increase of plasma 
immunoglobulin E and immunoglobulin G levels induced by the injection of 
syngeneic keratinocyte extracts in BALB/c mice. Clin Exp Allergy, 36(1), 102-110.  
Pagan, J. A., & Pauly, M. V. (2005). Access to conventional medical care and the use of 
complementary and alternative medicine. Health Aff (Millwood), 24(1), 255-262.  
Park, E. J., Kim, B., Eo, H., Park, K., Kim, Y., Lee, H. J., et al. (2005). Control of IgE and 
selective T(H)1 and T(H)2 cytokines by PG102 isolated from Actinidia arguta. J 
Allergy Clin Immunol, 116(5), 1151-1157.  
Park, E. J., Park, K. C., Eo, H., Seo, J., Son, M., Kim, K. H., et al. (2007). Suppression of 
spontaneous dermatitis in NC/Nga murine model by PG102 isolated from 
Actinidia arguta. J Invest Dermatol, 127(5), 1154-1160.  
www.intechopen.com
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 458 
Passeron, T., Lacour, J. P., Fontas, E., & Ortonne, J. P. (2006). Prebiotics and synbiotics: two 
promising approaches for the treatment of atopic dermatitis in children above 2 
years. Allergy, 61(4), 431-437.  
Peroni, D. G., Piacentini, G. L., Bodini, A., Rigotti, E., Pigozzi, R., & Boner, A. L. (2008). 
Prevalence and risk factors for atopic dermatitis in preschool children. Br J 
Dermatol, 158(3), 539-543.  
Pinnagoda, J., Tupker, R. A., Agner, T., & Serup, J. (1990). Guidelines for transepidermal 
water loss (TEWL) measurement. A report from the Standardization Group of the 
European Society of Contact Dermatitis. Contact Dermatitis, 22(3), 164-178.  
Presta, L. G., Lahr, S. J., Shields, R. L., Porter, J. P., Gorman, C. M., Fendly, B. M., et al. (1993). 
Humanization of an antibody directed against IgE. J Immunol, 151(5), 2623-2632.  
Rapaport, M. H., Nierenberg, A. A., Howland, R., Dording, C., Schettler, P. J., & Mischoulon, 
D. (2011). The treatment of minor depression with St. John's Wort or citalopram: 
Failure to show benefit over placebo. J Psychiatr Res, 45(7), 931-941.  
Rawson, N. S. (2000). Time required for approval of new drugs in Canada, Australia, 
Sweden, the United Kingdom and the United States in 1996-1998. CMAJ, 162(4), 
501-504.  
Sakuma, S., Higashi, Y., Sato, N., Sasakawa, T., Sengoku, T., Ohkubo, Y., et al. (2001). 
Tacrolimus suppressed the production of cytokines involved in atopic dermatitis 
by direct stimulation of human PBMC system. (Comparison with steroids). Int 
Immunopharmacol, 1(6), 1219-1226.  
Salameh, F., Perla, D., Solomon, M., Gamus, D., Barzilai, A., Greenberger, S., et al. (2008). 
The effectiveness of combined Chinese herbal medicine and acupuncture in the 
treatment of atopic dermatitis. J Altern Complement Med, 14(8), 1043-1048.  
Scalbert, A., & Williamson, G. (2000). Dietary intake and bioavailability of polyphenols. J 
Nutr, 130(8S Suppl), 2073S-2085S.  
Schachner, L., Field, T., Hernandez-Reif, M., Duarte, A. M., & Krasnegor, J. (1998). Atopic 
dermatitis symptoms decreased in children following massage therapy. Pediatr 
Dermatol, 15(5), 390-395.  
Schafer, T. (2004). Epidemiology of complementary alternative medicine for asthma and 
allergy in Europe and Germany. Ann Allergy Asthma Immunol, 93(2 Suppl 1), S5-10.  
Schafer, T., Riehle, A., Wichmann, H. E., & Ring, J. (2002). Alternative medicine in allergies - 
prevalence, patterns of use, and costs. Allergy, 57(8), 694-700.  
Schempp, C. M., Ludtke, R., Winghofer, B., & Simon, J. C. (2000). Effect of topical application 
of Hypericum perforatum extract (St. John's wort) on skin sensitivity to solar 
simulated radiation. Photodermatol Photoimmunol Photomed, 16(3), 125-128.  
Schmitt, J., Meurer, M., Schwanebeck, U., Grahlert, X., & Schakel, K. (2008). Treatment 
following an evidence-based algorithm versus individualised symptom-oriented 
treatment for atopic eczema. A randomised controlled trial. Dermatology, 217(4), 
299-308.  
Schrezenmeir, J., & de Vrese, M. (2001). Probiotics, prebiotics, and synbiotics--approaching a 
definition. Am J Clin Nutr, 73(2 Suppl), 361S-364S.  
SCORAD. (1993). Severity scoring of atopic dermatitis: the SCORAD index. Consensus 
Report of the European Task Force on Atopic Dermatitis. Dermatology, 186(1), 23-31.  
Sewitch, M. J., & Rajput, Y. (2010). A literature review of complementary and alternative 
medicine use by colorectal cancer patients. Complement Ther Clin Pract, 16(1), 52-56.  
www.intechopen.com
 
Natural Products and Dermatological Hypersensitivity Diseases 459 
Simpson, E. L., Berry, T. M., Brown, P. A., & Hanifin, J. M. (2010). A pilot study of emollient 
therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol, 63(4), 
587-593.  
Sirois, F. M., & Gick, M. L. (2002). An investigation of the health beliefs and motivations of 
complementary medicine clients. Soc Sci Med, 55(6), 1025-1037.  
Spergel, J. M., & Leung, D. Y. (2006). Safety of topical calcineurin inhibitors in atopic 
dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep, 6(4), 270-274.  
Stevens, S. R., Hanifin, J. M., Hamilton, T., Tofte, S. J., & Cooper, K. D. (1998). Long-term 
effectiveness and safety of recombinant human interferon gamma therapy for 
atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol, 134(7), 799-
804.  
Streiner, DL , & Normam, GL. (2009). Drug Trial Phases. Community Oncology, 6(1), 36-40.  
Strunk, R. C., & Bloomberg, G. R. (2006). Omalizumab for asthma. N Engl J Med, 354(25), 
2689-2695.  
Su, D., & Li, L. (2011). Trends in the use of complementary and alternative medicine in the 
United States: 2002-2007. J Health Care Poor Underserved, 22(1), 296-310.  
Suto, H., Matsuda, H., Mitsuishi, K., Hira, K., Uchida, T., Unno, T., et al. (1999). NC/Nga 
mice: a mouse model for atopic dermatitis. Int Arch Allergy Immunol, 120 Suppl 1, 
70-75.  
Szczepanowska, J., Reich, A., & Szepietowski, J. C. (2008). Emollients improve treatment 
results with topical corticosteroids in childhood atopic dermatitis: a randomized 
comparative study. Pediatr Allergy Immunol, 19(7), 614-618.  
Teelucksingh, S., Mackie, A. D., Burt, D., McIntyre, M. A., Brett, L., & Edwards, C. R. (1990). 
Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet, 
335(8697), 1060-1063.  
Tollesson, A., & Frithz, A. (1993). Borage oil, an effective new treatment for infantile 
seborrhoeic dermatitis. Br J Dermatol, 129(1), 95.  
Ukawa, Y., Ito, H., & Hisamatsu, M. (2000). Antitumor effects of (1-->3)-beta-D-glucan and 
(1-->6)-beta-D-glucan purified from newly cultivated mushroom, Hatakeshimeji 
(Lyophyllum decastes Sing.). J Biosci Bioeng, 90(1), 98-104.  
Ukawa, Y., Izumi, Y., Ohbuchi, T., Takahashi, T., Ikemizu, S., & Kojima, Y. (2007). Oral 
administration of the extract from Hatakeshimeji (Lyophyllum decastes sing.) 
mushroom inhibits the development of atopic dermatitis-like skin lesions in 
NC/Nga mice. J Nutr Sci Vitaminol (Tokyo), 53(3), 293-296.  
Υσηα Ρανι, ΜΥΡ Ναιδι. (2009). Phase 0 - Microdosing strategy in clinical trials. Indian Journal 
of Pharmacology, 40(6), 240-242.  
Vestergaard, C., Yoneyama, H., Murai, M., Nakamura, K., Tamaki, K., Terashima, Y., et al. 
(1999). Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting 
atopic dermatitis-like lesions. J Clin Invest, 104(8), 1097-1105.  
Viljanen, M., Savilahti, E., Haahtela, T., Juntunen-Backman, K., Korpela, R., Poussa, T., et al. 
(2005). Probiotics in the treatment of atopic eczema/dermatitis syndrome in 
infants: a double-blind placebo-controlled trial. Allergy, 60(4), 494-500.  
Wallach, D., Coste, J., Tilles, G., & Taieb, A. (2005). The first images of atopic dermatitis: an 
attempt at retrospective diagnosis in dermatology. J Am Acad Dermatol, 53(4), 684-
689.  
www.intechopen.com
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 460 
WHO. (2005). National policy on traditional medicine and regulation of herbal medicines : report of 
a WHO global survey. Geneva: World Health Organization. 
Wichers, H. (2009). Immunomodulation by food: promising concept for mitigating allergic 
disease? Anal Bioanal Chem, 395(1), 37-45.  
Wiles, J., & Rosenberg, M. W. (2001). 'Gentle caring experience'. Seeking alternative health 
care in Canada. Health Place, 7(3), 209-224.  
Williams, H. (1992). Is the prevalence of atopic dermatitis increasing? Clin Exp Dermatol, 
17(6), 385-391.  
Williams, H. . (2003). Evening primrose oil for atopic dermatitis. BMJ, 327(7428), 1358-1359.  
Wise, F., & Sulzberger, MG. (1933). In Year Book of Dermatology and Syphiolology. 
World Health Organization. (2009). Report of the WHO Interregional Workshop on the Use of 
Traditional Medicine in Primary Health Care : Ulaanbaatar, Mongolia, 23-26 August 
2007. Geneva: World Health Organization. 
Wright, S. (1991). Essential fatty acids and the skin. Br J Dermatol, 125(6), 503-515.  
www.intechopen.com
Allergic Diseases - Highlights in the Clinic, Mechanisms and
Treatment
Edited by Prof. Celso Pereira
ISBN 978-953-51-0227-4
Hard cover, 554 pages
Publisher InTech
Published online 14, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The present Edition "Allergic diseases - highlights in the clinic, mechanisms and treatment" aims to present
some recent aspects related to one of the most prevalent daily clinical expression disease. The effort of a
group of outstanding experts from many countries reflects a set of scientific studies very promising for a better
clinical care and also to the treatment and control of the allergy. This book provides a valuable reference text
in several topics of the clinical allergy and basic issues related to the immune system response. The
inflammatory reaction understanding in allergic disease is clearly evidenced, as well as new strategies for
further researches.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Clayton MacDonald and Marianna Kulka (2012). Natural Products and Dermatological Hypersensitivity
Diseases, Allergic Diseases - Highlights in the Clinic, Mechanisms and Treatment, Prof. Celso Pereira (Ed.),
ISBN: 978-953-51-0227-4, InTech, Available from: http://www.intechopen.com/books/allergic-diseases-
highlights-in-the-clinic-mechanisms-and-treatment/naturally-sourced-bioactives-are-a-promising-source-of-
novel-allergy-therapies
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
